Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.44) by 77.27 percent. This is a 70.59 percent increase over losses of $(0.34) per share from the same period last year.
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $250
Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $200 to $250.
